As per our analysis, the Europe High Potency APIs (HPAPI) Market size was valued at USD 5.32 billion in 2019 and estimated to be growing at a CAGR of 8.7%, to reach USD 8.07 billion by 2024 during the forecast period 2019-2024.
High Potency APIs (HPAPI) are pharmacological intermediates and substances which are active at concentrations of 150 micrograms per kilogram of body weight or below. They are very selective in nature, hence can bind to specific receptors or to specific enzymes which can cause cancer, developmental disorders, and reproductive problems at low doses. Since many new drugs have HPAPI’s the growth of this market is high.
High Potency APIs (HPAPI) have a wide range of applications for the treatment of many diseases of which cancer drugs are popular. After the mapping of the human genome, drugs for cancer could be made not only for different cancers but also for different patients. However, since these drugs are active at very low concentrations, they have to be manufactured with great care. They can pose health dangers to workers if proper care is not taken during production. Effective monitoring has to be done to prevent contamination of drugs with contaminants. So it requires specialized equipment for handling HPAPI’s and managing air quality.
The High Potency Active Pharmaceutical Ingredients market in Europe is driven by factors like their low price, rising healthcare prices growing number of pharmaceutical manufacturers, patients and increasing government initiatives to expand the usage of generic medicines to cut down healthcare costs.
However, the market is constrained by stringent regulatory requirements, the high price of equipment and lack of skilled workers.
This research report has been segmented and sub-segmented into the following categories:
There have been large investments in the Europe region for the HPAPI market in recent times. Factors such as rising incidence of cancer increased funding in cancer research and development of new drugs is expected to drive the market in this region.
Key companies in the Europe High Potency API (HPAPI) Market Profiled in the Report are Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.1 Innovative HPAPI's
5.1.2 Generic HPAPI's
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, By Type
5.2.1 Biotech HPAPI's
188.8.131.52 Biotech High- otency Active Pharmaceutical Ingredients Market, By Type
184.108.40.206.1 Innovative Biotech HPAPIs
5.2.2 Synthetic HPAPI's
220.127.116.11 Synthetic High Potency Active Pharmaceutical Ingredients Market, By Type
18.104.22.168.1 Innovative Synthetic HPAPIs
22.214.171.124.2 Generic Synthetic HPAPIs
5.2.3 Y-o-Y Growth Analysis, By Synthesis
5.2.4 Market Attractiveness Analysis, By Synthesis
5.2.5 Market Share Analysis, By Synthesis
5.3 Therapeutic Application
5.3.3 Hormonal Balance
5.3.4 Other therapeutic applications
5.3.5 Y-o-Y Growth Analysis, By Therapeutic Application
5.3.6 Market Attractiveness Analysis, By Therapeutic Application
5.3.7 Market Share Analysis, By Therapeutic Application
5.4.1 Captive Manufacturers
5.4.2 Merchant Manufacturers
126.96.36.199 Merchant HPAPI Manufacturers Market, By Type
188.8.131.52.1 Innovative Merchant HPAPI Manufacturers
184.108.40.206.2 Generic Merchant HPAPI Manufacturers
220.127.116.11 Merchant HPAPI Manufacturers Market, By Type of Synthesis
18.104.22.168.1 Synthetic HPAPIs
22.214.171.124.2 Biotech HPAPIs
5.4.3 Y-o-Y Growth Analysis, By Manufacturer
5.4.4 Market Attractiveness Analysis, By Manufacturer
5.4.5 Market Share Analysis, By Manufacturer
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Type
188.8.131.52 By Synthesis
184.108.40.206 By Therapeutic Application
220.127.116.11 By Manufacturer
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Type
22.214.171.124 By Synthesis
126.96.36.199 By Therapeutic Application
188.8.131.52 By Manufacturer
6.1.5 Market Share Analysis
184.108.40.206 By Type
220.127.116.11 By Synthesis
18.104.22.168 By Therapeutic Application
22.214.171.124 By Manufacturer
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis International AG
8.4 F. Hoffmann-La Roche Ltd.
8.5 Eli Lilly and Company
8.6 Bristol-Myers Squibb
8.7 Boehringer Ingelheim
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Merck & Co., Inc.
8.10 AbbVie Inc.
8.11 Mylan Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures